Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort
Global Health, Epidemiology and Genomics · 2024
DOI: 10.1155/2024/9293896 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Health, Epidemiology and Genomics, 2024. Verfasst von Sebastián Jaurretche und 12 weiteren Autor:innen. Beteiligte Einrichtung: Transplant Department, Sanatorio Parque de Rosario, Rosario, Argentina. Hauptthemen laut MEDLINE: Fabry Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fabry disease (FD) is a multisystem lysosomal storage disorder induced by genetic variants in the alpha-galactosidase A (αGalA) gene. Some FD patients have GLA variants with a reduction in overall αGalA enzymatic activity due to mutated proteins with reduced stability, caused by protein misfolding and premature degradation, but the αGalA catalytic activity remains conserved (“amenable” genetic variants). To correct this misfolding and to prevent premature degradation, migalastat, a small iminosugar molecule was developed. We report the clinical characteristics of FD “amenable” cohort patients from Argentina, prior to starting treatment with migalastat. Seventeen Fabry adult patients were recruited from 13 Argentinian Centers; 8 males (47.1%) and 9 females (52.9%) were included. All genotypes included were missense-type “amenables” mutations. Some classic FD typical early manifestations were more frequent in patients with “classic” versus “late-onset” FD phenotype (pain, p = 0.002 ; cornea verticillata, p = 0.019 ). There was a statistically significant difference in estimated glomerular filtration rate in the “classic” versus “late-onset” phenotype ( p = 0.026 ) but no difference between genders ( p = 0.695 ). Left ventricular mass was similar between genders ( p = 0.145 ) and phenotypes ( p = 0.303 ). Cardiovascular risk factors were present among “late-onset” females (obesity 50% and smoke 25%). In patients who started “de novo” migalastat, the main indications were (i) heart disease, (ii) kidney damage, and (iii) pain, while in “switched from prior enzyme replacement therapy” patients, the most frequent indication was “patient decision;” this coincides with publications by other authors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Transplant Department, Sanatorio Parque de Rosario, Rosario, Argentina.
- Biophysics and Human Physiology, Instituto Universitario Italiano de Rosario, Rosario, Argentina.
- Angel C. Padilla Hospital, San Miguel de Tucumán, Argentina.
- STR Cuidadela, Buenos Aires, Argentina.
- Instituto de Nefrología y Hemodiálisis, Mendoza, Argentina.
- Rheumatology Department, Juan Domingo Perón Hospital, Formosa, Argentina.
ORCID-Profile: Sebastián Jaurretche
Zitieren
APA
Jaurretche, S., Alonso, S., Calvo, M., Fernandez, S., Figueredo, H., Galli, B., Marin, I., Martinez, A., Mattausch, S., Perretta, F., Politei, J., Rolon, J. I., & Calabrese, E. (2024). Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort. Global Health, Epidemiology and Genomics. https://doi.org/10.1155/2024/9293896
Vancouver
Jaurretche S, Alonso S, Calvo M, Fernandez S, Figueredo H, Galli B, et al. Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort. Global Health, Epidemiology and Genomics. 2024. doi:10.1155/2024/9293896
BibTeX
@article{Jaurretche2024,
author = {Jaurretche, Sebastián and Alonso, Santiago and Calvo, Mónica and Fernandez, Sebastián and Figueredo, Heber and Galli, Beatriz and Marin, Ivanna and Martinez, Andrés and Mattausch, Silvia and Perretta, Fernando and Politei, Juan and Rolon, Juan Ignacio and Calabrese, Esteban},
title = {Baseline Characteristics of Fabry Disease “Amenable” Migalastat Patients in Argentinian Cohort},
journal = {Global Health, Epidemiology and Genomics},
year = {2024},
doi = {10.1155/2024/9293896}
}
EUVIMED